Anna Karmann MD, PhD, MBA

Anna Karmann has over 20 years of experience in the biopharma industry, drug development, and clinical practice. As a board-certified Radiologist, she has deep expertise in medical imaging, radiobiology, and radiopharmaceutical therapies. Most recently, Anna was an executive at RayzeBio where she led the development of early-stage assets and provided strategic and clinical leadership for the GPC3 and CA9 programs to IND. Anna led and executed global compassionate use trials, which significantly contributed to the successful IPO and subsequent acquisition of the firm.

Before RayzeBio, Anna was a management consultant at McKinsey & Company where she successfully led projects for pharmaceutical, biotech, and investor clients with a focus on clinical development, targeted oncology, portfolio and commercial strategy, and operational performance. Anna holds an MD from RWTH Aachen University, a PhD from Maastricht University, and an MBA from RWTH Aachen University and Tsinghua University Beijing. She gained significant clinical practice and clinical research experience at the University Medical Center Maastricht, Netherlands, and Stanford University Hospital, CA, USA.